用FLT3抑制剂作为MRD引导的救援治疗,用于FLT3突变AML中的分子衰竭
Jad Othman1,2,3, Nicola Potter1, Katya Mokretar4
1Department of Medical and Molecular Genetics, King's College London, London, England, UK.
Leukemia
|August 9, 2023
概括
FLT3 抑制剂 (FLT3i) 显示为治疗 FLT3 突变的 AML 患者,在初始治疗后出现分子衰竭. 这种干预导致了分子反应和改善的生存率,这表明了预防复发的可行策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 患有FLT3突变急性髓性白血病 (AML) 的患者面临高复发率和不良结果.
- 通过RT-qPCR进行可测量的残留疾病 (MRD) 监测,可以识别患有复发 (分子衰竭) 风险的患者.
- 仅有有限的证据可指导针对FLT3突变AML分子衰竭的预防性干预措施.
研究的目的:
- 评估FLT3抑制剂 (FLT3i) 作为FLT3突变AML分子衰竭患者单一治疗策略的疗效和安全性.
- 评估FLT3i对该患者队列分子反应,存活率和移植资格的影响.
主要方法:
- 对56名FLT3突变AML患者的回顾性分析,这些患者在分子衰竭时接受FLT3i (吉尔特利尼布,奎萨提尼布或索拉芬尼布) 治疗.
- 分析FLT3突变类型 (ITD,TKD),先前的治疗和结果,包括分子反应,毒性和存活率.
- 利用FLT3-ITD的高灵敏度下一代测序来识别潜在的益处预测因素.
主要成果:
- 60%的患者获得了分子反应,其中45%在FLT3i治疗后达到MRD阴性.
- 观察到低水平的血液毒性.
- 实现了与异构移植 (22 位患者) 或输注捐赠淋巴细胞 (6 位患者) 之间的显著桥梁.
- 两年总生存率为80%,无分子事件生存率为56%.
结论:
- 单一治疗FLT3抑制剂是一种有前途的策略,用于管理FLT3突变AML中的分子衰竭.
- 这种方法可以导致分子缓解,改善存活率,并促进全原干细胞移植.
- 有必要进行前性研究,以进一步评估FLT3i在AML中的分子衰竭.
更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.4K
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
174
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
